Skip to content
Riskpilot
← Back to search
Sign in
Get full access
AlgiPharma AB
AB
In liquidation
Org 5592149826
Research and experimental development on biotechnology
·
NACE 7211
Est. 2019 · 6 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on biotechnology
/
AlgiPharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (5)
JA
Jan Anders Fredrik Lovén
Liquidator
Liquidator
2024
AM
Anna Matilda Sjödin
External Signatory
External Signatory
2024
WL
Wendy Lissette Fahlgren
Liquidator
Liquidator
2024
ME
Mattias Eriksson
Audit
Audit
2024
AC
Ann Charlott Bouvin
Auditor Substitute
Auditor Substitute
2024
Former (2)
YP
Yngvar Peter Berg
Chief Executive Officer
Chief Executive Officer
2020 – 2024
ET
Eva Therese Kjellberg
Chief Auditor
Chief Auditor
2020 – 2024
Board of directors
Non-executive oversight
Name
Role
Member since
Former (3)
DS
Diderik Schnitler
Board of Directors
Board of Directors
2022 – 2024
AD
Arne Dessen
Chairman
Chairman
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on AlgiPharma AB
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
2020 – 2024
FV
Fredrik Veimar Alpsten
Board of Directors
Board of Directors
2020 – 2021
